USO 24265

ISANG PHASE II, OPEN-LABEL, MULTICENTER NA PAG-AARAL UPANG MASUSURI ANG PAG-OPTIMIZATION NG CYTOKINE RELEASE SYNDROME PROFILE PARA SA GLOFITAMAB KASAMA ANG GEMCITABINE PLUS OXALIPLATIN SA MGA PASYENTE NA MAY RELAPSED/REFRACTORY BHOUSEGOELLA44(REFRACTORY BHOUSELL4)4

Mga Uri ng Sakit: Leukemia at Lymphoma Research

Mga Kinakailangan sa Kwalipikasyon:

Histologically confirmed DLBCL, not otherwise specified (NOS)
R/R disease, defined as: relapsed = disease that has recurred following a response that lasted >/= 6 months after completion of the last line of therapy; refractory = disease that did not respond to or that progressed < 6 months after completion of the last line of therapy
At least one line of prior systemic therapy
Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)
At least one bi-dimensionally measurable (> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (> 1 cm) extranodal lesion, as measured on CT scan
Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2
Adequate hematologic and renal function

Para sa karagdagang impormasyon sa pagsubok na ito CLICK HERE .

Available sa:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Virginia Beach ( Princess Anne )
• Williamsburg
• Norfolk (Brock Cancer Center)